130 related articles for article (PubMed ID: 38743401)
21. Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae.
Zheng M; Li FH; Liu J; Li WJ; Yin RX; Cai DT; Andrey DO; Zheng SL; Gales AC; Zhang WJ; Sun J; Liao XP; Yu Y
J Antimicrob Chemother; 2024 May; 79(5):1069-1080. PubMed ID: 38526879
[TBL] [Abstract][Full Text] [Related]
22. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.
Göttig S; Frank D; Mungo E; Nolte A; Hogardt M; Besier S; Wichelhaus TA
J Antimicrob Chemother; 2019 Nov; 74(11):3211-3216. PubMed ID: 31365094
[TBL] [Abstract][Full Text] [Related]
23. Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates.
Carattoli A; Arcari G; Bibbolino G; Sacco F; Tomolillo D; Di Lella FM; Trancassini M; Faino L; Venditti M; Antonelli G; Raponi G
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0057421. PubMed ID: 34339281
[TBL] [Abstract][Full Text] [Related]
24. Increased gene expression and copy number of mutated bla
Sun L; Li H; Wang Q; Liu Y; Cao B
BMC Microbiol; 2021 Aug; 21(1):230. PubMed ID: 34412588
[TBL] [Abstract][Full Text] [Related]
25. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S
Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422
[TBL] [Abstract][Full Text] [Related]
26. Emergence of ceftazidime-avibactam resistance due to a novel blaKPC-2 mutation during treatment of carbapenem-resistant Klebsiella pneumoniae infections.
Liao Q; Deng J; Feng Y; Zhang W; Wu S; Liu Y; Che H; Xie Y
J Infect Public Health; 2022 May; 15(5):545-549. PubMed ID: 35461077
[TBL] [Abstract][Full Text] [Related]
27. Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: A case series.
van Asten SAV; Boattini M; Kraakman MEM; Bianco G; Iannaccone M; Costa C; Cavallo R; Bernards AT
J Infect Chemother; 2021 May; 27(5):778-780. PubMed ID: 33558042
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
29. First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197.
De la Cadena E; Mojica MF; Rojas LJ; Castro BE; García-Betancur JC; Marshall SH; Restrepo N; Castro-Caro NP; Fonseca-Carrillo M; Pallares C; Bonomo RA; Villegas MV
Microbiol Spectr; 2024 Jun; 12(6):e0410523. PubMed ID: 38700337
[TBL] [Abstract][Full Text] [Related]
30. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
Papadimitriou-Olivgeris M; Bartzavali C; Lambropoulou A; Solomou A; Tsiata E; Anastassiou ED; Fligou F; Marangos M; Spiliopoulou I; Christofidou M
J Antimicrob Chemother; 2019 Jul; 74(7):2051-2054. PubMed ID: 31002313
[TBL] [Abstract][Full Text] [Related]
31. Outbreak of Klebsiella pneumoniae ST11 Resistant To Ceftazidime-Avibactam Producing KPC-31 and the Novel Variant KPC-115 during COVID-19 Pandemic in Argentina.
Nicola F; Cejas D; González-Espinosa F; Relloso S; Herrera F; Bonvehí P; Smayevsky J; Figueroa-Espinosa R; Gutkind G; Radice M
Microbiol Spectr; 2022 Dec; 10(6):e0373322. PubMed ID: 36445147
[TBL] [Abstract][Full Text] [Related]
32. Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.
Hobson CA; Cointe A; Jacquier H; Choudhury A; Magnan M; Courroux C; Tenaillon O; Bonacorsi S; Birgy A
Clin Microbiol Infect; 2021 Aug; 27(8):1172.e7-1172.e10. PubMed ID: 33915286
[TBL] [Abstract][Full Text] [Related]
33. Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.
Hernández-García M; Castillo-Polo JA; Cordero DG; Pérez-Viso B; García-Castillo M; Saez de la Fuente J; Morosini MI; Cantón R; Ruiz-Garbajosa P
J Clin Microbiol; 2022 Mar; 60(3):e0224521. PubMed ID: 35107303
[TBL] [Abstract][Full Text] [Related]
34. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.
Gaibani P; Campoli C; Lewis RE; Volpe SL; Scaltriti E; Giannella M; Pongolini S; Berlingeri A; Cristini F; Bartoletti M; Tedeschi S; Ambretti S
J Antimicrob Chemother; 2018 Jun; 73(6):1525-1529. PubMed ID: 29566151
[TBL] [Abstract][Full Text] [Related]
35. Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City.
Manning N; Balabanian G; Rose M; Landman D; Quale J
Microb Drug Resist; 2018; 24(1):35-39. PubMed ID: 28590820
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
[No Abstract] [Full Text] [Related]
37. A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring
Niu S; Chavda KD; Wei J; Zou C; Marshall SH; Dhawan P; Wang D; Bonomo RA; Kreiswirth BN; Chen L
mSphere; 2020 Aug; 5(4):. PubMed ID: 32848008
[TBL] [Abstract][Full Text] [Related]
38. Multiple Novel Ceftazidime-Avibactam-Resistant Variants of
Shi Q; Han R; Guo Y; Yang Y; Wu S; Ding L; Zhang R; Yin D; Hu F
Microbiol Spectr; 2022 Jun; 10(3):e0171421. PubMed ID: 35588280
[TBL] [Abstract][Full Text] [Related]
39. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.
Shields RK; Clancy CJ; Hao B; Chen L; Press EG; Iovine NM; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2015 Sep; 59(9):5793-7. PubMed ID: 26169413
[TBL] [Abstract][Full Text] [Related]
40. Ceftazidime-Avibactam Resistance Associated with Increased
Coppi M; Di Pilato V; Monaco F; Giani T; Conaldi PG; Rossolini GM
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
